The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Robert G. Maki

Memorial Sloan-Kettering Cancer Center

New York

NY 10065-6007



Name/email consistency: high



  • Memorial Sloan-Kettering Cancer Center, New York, NY 10065-6007, USA. 2010
  • Melanoma-Sarcoma Program, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, USA. 2001 - 2009


  1. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. Maki, R.G. J. Clin. Oncol. (2010) [Pubmed]
  2. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. Maki, R.G., D'Adamo, D.R., Keohan, M.L., Saulle, M., Schuetze, S.M., Undevia, S.D., Livingston, M.B., Cooney, M.M., Hensley, M.L., Mita, M.M., Takimoto, C.H., Kraft, A.S., Elias, A.D., Brockstein, B., Blachère, N.E., Edgar, M.A., Schwartz, L.H., Qin, L.X., Antonescu, C.R., Schwartz, G.K. J. Clin. Oncol. (2009) [Pubmed]
  3. Pediatric sarcomas occurring in adults. Maki, R.G. J. Surg. Oncol (2008) [Pubmed]
  4. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Maki, R.G. Oncologist (2007) [Pubmed]
  5. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Maki, R.G., Livingston, P.O., Lewis, J.J., Janetzki, S., Klimstra, D., Desantis, D., Srivastava, P.K., Brennan, M.F. Dig. Dis. Sci. (2007) [Pubmed]
  6. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. Maki, R.G., Wathen, J.K., Patel, S.R., Priebat, D.A., Okuno, S.H., Samuels, B., Fanucchi, M., Harmon, D.C., Schuetze, S.M., Reinke, D., Thall, P.F., Benjamin, R.S., Baker, L.H., Hensley, M.L. J. Clin. Oncol. (2007) [Pubmed]
  7. Future directions for immunotherapeutic intervention against sarcomas. Maki, R.G. Curr. Opin. Oncol (2006) [Pubmed]
  8. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Maki, R.G., Kraft, A.S., Scheu, K., Yamada, J., Wadler, S., Antonescu, C.R., Wright, J.J., Schwartz, G.K. Cancer (2005) [Pubmed]
  9. Gastrointestinal Stromal Tumors Respond to Tyrosine Kinase-targeted Therapy. Maki, R.G. Curr. Treat. Options. Gastroenterol (2004) [Pubmed]
  10. Role of chemotherapy in patients with soft tissue sarcomas. Maki, R.G. Expert. Rev. Anticancer. Ther (2004) [Pubmed]
  11. Immunity against soft-tissue sarcomas. Maki, R.G. Curr. Oncol. Rep (2003) [Pubmed]
  12. Multidisciplinary management of soft-tissue sarcomas. Maki, R.G. Cancer Invest. (2002) [Pubmed]
  13. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Maki, R.G., Awan, R.A., Dixon, R.H., Jhanwar, S., Antonescu, C.R. Int. J. Cancer (2002) [Pubmed]
  14. Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Maki, R.G. Curr. Opin. Oncol (2001) [Pubmed]
  15. Sarcoma. Maki, R. Oncologist (2001) [Pubmed]
WikiGenes - Universities